|
EP3551617A1
|
|
Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
|
|
WO2011123654A1
|
|
Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
|
|
CN102753171A
|
|
Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
|
|
US2010256229A1
|
|
Compositions of cholinesterase inhibitors
|
|
WO2010009316A1
|
|
Stigmine conjugates for substance use disorders
|
|
AU2008276459A1
|
|
Methods for promoting wakefulness
|
|
MX2010000624A
|
|
Methods for promoting wakefulness.
|
|
AU2008214380A1
|
|
Compounds that inhibit cholinesterase
|
|
CN101631770A
|
|
The compound that suppresses Pseudocholinesterase
|
